Study Finds No Association With Increased Heart Failure Study finds sickle cell trait not linked to risks in heart function in African Americans Thursday, Dec. 08, 2016 Study finds sickle cell trait...

Mutation in Bone Cells May Cause Leukemia Research finds that certain DNA mutations in bone cells can drive leukemia formation in nearby blood stem Wednesday, Oct. 26, 2016 Research finds that...

Diagnosing Blood Disorders Through A Strength Test Aflac Cancer and Blood Disorders Center study on platelets published in Nature Monday, Oct. 10, 2016 Aflac Cancer and Blood Disorders Center study...

A team of researchers from Emory, Children’s Healthcare of Atlanta and Georgia Tech showed in a paper, published in Nature Biotechnology, that scientists and researchers can improve protein-based drugs by reaching into the evolutionary past.

Doctors at Children’s are encouraging parents and professionals to learn a more improved form of swaddling, which includes leaving room at the bottom of the blanket for the infant’s hips and legs to move freely. This new initiative aims to reduce hip dysplasia in infants

A new compound has shown promise in preclinical studies as a treatment for acute myeloid leukemia, more than doubling median days of survival even in a drug-resistant form of the disease.

Leading national children’s hospitals, including Children's, along with pediatric cancer organizations and academic centers unite with Cancer MoonShot 2020. The consortium aims to accelerate bringing the next-generation standard of cancer care and immunotherapy to children with cancer.

The Aflac Cancer & Blood Disorders Center of Children’s Healthcare of Atlanta has been named a host institution for a collaborative international study sponsored by Novartis. This is a clinical trial analyzing the safety and effectiveness of an investigational cellular therapy treatment for children fighting cancer.

he sickle cell program at the Aflac Cancer & Blood Disorders Center of Children’s Healthcare of Atlanta has been named the lead coordinating center for a National Institute of Health (NIH) study to determine the safety and effectiveness of bone marrow transplants (BMT) compared to standard care therapies to cure sickle cell disease in young adult patients.

After 15 years of dedicated service, William G. Woods, M.D., has stepped down as director of the Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta and chief of hematology/oncology/BMT in the Department of Pediatrics at Emory University. He will be succeeded by Douglas Graham, M.D., Ph.D.